Latest Csl News

Page 1 of 6
Avecho has resumed recruitment for the final cohort of its pivotal Phase III insomnia trial after an interim review supported continuing at the original 519-participant target. The biotechnology company is also pursuing international licensing while holding $5.3 million in cash.
Ada Torres
Ada Torres
28 Oct 2026
Clever Culture Systems has fully invoiced three APAS Independence sales in the first quarter of FY27 and expects customer commitments to lift first-half sales and evaluations to eight instruments. A new paid evaluation with a Top-20 pharmaceutical company could expand its base of major drugmakers to nine, although several milestones remain prospective.
Victor Sage
Victor Sage
28 Oct 2026
Barramundi’s portfolio returned 3.0% on a gross basis in the September quarter, ahead of the ASX 200’s 1.3% gain. CSL, Ansell, MAAS Group and PWR Holdings led the recovery, although the NZX-listed investment company still traded at a 17.2% discount to NAV.
Victor Sage
Victor Sage
28 Oct 2026
CSL has been named as the defendant in a group proceeding filed in the Supreme Court of Victoria, covering investors who acquired certain securities between February 2025 and May 2026. The company denies liability and says it will vigorously defend allegations involving continuous disclosure and FY26 performance statements.
Ada Torres
Ada Torres
22 Oct 2026
CSL has appointed ViiV Healthcare CEO Deborah Waterhouse to lead the biopharmaceutical group from 1 February 2027. Her arrival comes with a substantial UK-pound-denominated remuneration package and a mandate to renew the pipeline while simplifying operations.
Ada Torres
Ada Torres
21 Oct 2026
BCI Minerals has pushed the Mardie project to 90% construction completion, while crystallised salt rose more than fivefold to 266,000 tonnes during the September quarter. The company still targets first salt on ship in calendar 2027, but the timetable depends on summer evaporation and the final commissioning push.
Maxwell Dee
Maxwell Dee
20 Oct 2026
Noxopharm has completed its first-in-human safety trial for SOF-SKN and advanced the wider Sofra platform, but its annual report flags a material uncertainty over funding. The biotech ended June with A$293,573 in cash, net liabilities of A$3.65 million and a need for additional capital.
Ada Torres
Ada Torres
16 Oct 2026
Plato Income Maximiser matched its benchmark with a 7.2% portfolio return in FY26 while maintaining its highest monthly dividend rate since listing. Profit after tax fell to A$41.8 million as investment gains dropped sharply from the prior year.
Claire Turing
Claire Turing
14 Oct 2026
Clime Capital delivered a sharply stronger FY26 result, with after-tax profit rising to $10.3 million and dividends maintained. But KPMG qualified its audit after failing to obtain sufficient evidence for $36.2 million of unlisted unit trust valuations and related income and fees.
Claire Turing
Claire Turing
5 Oct 2026
CSL has secured an exclusive agreement to co-develop and co-promote Alentis Therapeutics’ investigational drug lixudebart, committing US$355 million upfront and funding a multi-trial development programme. The antibody remains unapproved, with its commercial potential dependent on results from ongoing and planned clinical studies.
Victor Sage
Victor Sage
5 Oct 2026
Barramundi Limited (NZX:BRM) has reported the worst performance in its 20-year history, with a NZ$42.9 million net loss and a 17.0% fall in gross portfolio performance. The board is reviewing Fisher Funds’ management performance just weeks before its five-year agreement comes up for renewal.
Claire Turing
Claire Turing
28 Sept 2026
Cadence Capital delivered a sharply stronger FY2026, with profit after tax rising to $33.4 million and its portfolio returning 20.1% against the All Ordinaries Accumulation Index. The listed investment company also moved decisively away from gold and resources, ending the year with $153.5 million in cash and a further 1.0 cent fully franked special dividend on the way.
Victor Sage
Victor Sage
22 Sept 2026

Browse the archive

Full archive